AVIDITY BIOSCIENCES INC (RNA)
US05370A1088 - Common Stock
AVIDITY BIOSCIENCES INC
NASDAQ:RNA (10/21/2024, 8:00:02 PM)
After market: 47 +0.29 (+0.62%)46.71
-3.74 (-7.41%)
Company Profile
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). The company is headquartered in San Diego, California and currently employs 253 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.
Company Info
AVIDITY BIOSCIENCES INC
10578 Science Center Drive, Suite 125
San Diego CALIFORNIA 92037
P: 18584017900
CEO: Sarah Boyce
Employees: 253
Website: https://www.aviditybiosciences.com/
RNA News
14 hours ago - Avidity Biosciences, Inc.Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
4 days ago - Investor's Business DailyAvidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats UpThe company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.
15 days ago - ChartmillMonday's after hours session: top gainers and losersCurious about the stocks that are showing activity after the closing bell on Monday?
17 days ago - The Motley FoolWhy Avidity Biosciences Zoomed to a 12% Gain This WeekThe company's most promising pipeline program can continue unabated.
19 days ago - Avidity Biosciences, Inc.Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
a month ago - Avidity Biosciences, Inc.Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...
RNA Twits
Here you can normally see the latest stock twits on RNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
